Overview

Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with non-valvular AF treated with Xarelto, in accordance with the terms of the European marketing authorization and the Belgian reimbursement criteria.

Details

Lead Sponsor:

Bayer

Collaborator:

Janssen Scientific Affairs, LLC

Treatments:

Rivaroxaban